Developer docs
API playgroundTry for free, no card

Search company profiles

Nuformix

Full company profile

uuid003fk6z

Namestring
Nuformix
Legal namestring
Nuformix plc
Websiteurl
nuformix.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Nuformix plc is a UK-domiciled, London Stock Exchange-listed (ticker NFX) pharmaceutical development company that applies solid-form science and drug-repurposing expertise to create differentiated formulations of marketed compounds for fibrosis and oncology indications. Founded in 2008 (rebranded from Levrett PLC in September 2017), the company operates a virtual R&D model: three Directors plus a scientific consultant oversee development outsourced to a contracted network, with no in-house laboratory infrastructure.

Its pipeline comprises three assets. NXP002 is an inhaled formulation of tranilast for idiopathic pulmonary fibrosis (IPF), which reported positive preclinical results in March 2023 and received FDA Orphan Drug Status in March 2026, conferring US tax credits, fee waivers, and seven years of market exclusivity. NXP001 is a proprietary new form of aprepitant for oncology supportive care, exclusively licensed to Oxilio Ltd in September 2021 in a deal yielding upfront, development milestones, and royalties on net sales capped at £2 million per annum. NXP004 consists of novel co-crystal forms of olaparib (an oncology drug with annual sales exceeding £1 billion); two patent applications filed in September 2020 and November 2021 could extend exclusivity to 2040/2041 if granted.

The business model is asset-centric licensing rather than product sales. Nuformix takes each asset to a value inflection point — typically preclinical proof-of-concept or regulatory designation — before seeking global out-licensing deals with pharmaceutical partners. Capital comes from periodic equity placings (March 2021, October 2024, May 2025, October 2025) supplemented by non-dilutive grant funding. No commercial product revenue is generated; near-term cash inflows depend on licensing milestones and royalties under the Oxilio agreement.

Short descriptiontext

Nuformix is a UK-listed virtual pharmaceutical development company using solid-form science and drug repurposing to advance three preclinical/late-discovery assets — NXP001, NXP002, and NXP004 — for fibrosis and oncology, monetising them through out-licensing to pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical drug development, drug repurposing technology, solid form science, fibrosis therapeutics, oncology drug development
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

The company generates revenue through licensing its proprietary drug candidates to pharmaceutical partners. This includes upfront payments, development milestone payments, and royalties on net sales. For NXP001 licensing with Oxilio, Nuformix receives an undisclosed upfront payment, development milestone payments, and a royalty on net sales capped at £2 million per annum.

nuformix.com
2Non-dilutive Grant Funding
TypeManaged Services
Description

The company seeks ongoing non-dilutive grant funding for early-stage assets that, if successful, will enable further investment in the pipeline to accelerate development and potential licensing opportunities.

nuformix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nuformix is a pharmaceutical development company that uses proprietary solid form science and cocrystal technology to discover, develop and patent novel drug forms of marketed compounds, repurposing them into differentiated therapeutic candidates for fibrosis and oncology. The company operates a virtual development model, advancing assets to key value inflection points before licensing them to pharmaceutical partners for upfront fees, development milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Shares increased 12.5% following FDA Orphan Drug Status grant for NXP002
+2 more records
Product overview1 text field

Nuformix is a pharmaceutical development company with an early-stage pipeline of three preclinical and Phase 1-ready assets targeting fibrosis and oncology through drug repurposing. The company's core products include NXP002 (inhaled tranilast for idiopathic pulmonary fibrosis), NXP001 (novel form of aprepitant for oncology, licensed to Oxilio), and NXP004 (novel form of olaparib for oncology). Nuformix uses expertise in solid form science to discover, develop, and patent novel drug forms with improved physical properties to create differentiated products in new indications.

Product and service3 records
1NXP002 (inhaled tranilast)
CategoryInhaled fibrosis therapy
Description

Lead asset and potential novel inhaled treatment for idiopathic pulmonary fibrosis (IPF). An inhaled formulation of tranilast delivered directly to the lungs by inhalation, targeting TGFβ/SMAD2-mediated extra-cellular matrix protein production. Preclinical data demonstrated efficient lung delivery with significant drug levels and limited systemic exposure compared to oral dosing, and dose-dependent regulation of fibrosis-relevant mediators.

2NXP001 (proprietary new form of aprepitant)
CategoryOncology supportive care
Description

Proprietary new form of aprepitant for oncology supportive care and oncology indications, demonstrating bioavailability similar to the marketed product without requiring complex formulation. Out-licensed exclusively to Oxilio Ltd on 10 September 2021 for global research, development and commercialisation in oncology indications in exchange for undisclosed upfront, development milestones, and royalties on net sales capped at £2 million per annum.

3NXP004 (novel co-crystal forms of olaparib)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-10
Description

Exclusive global licensing agreement signed on September 10, 2021 with Oxilio Ltd, a privately held pharmaceutical development company, for NXP001 (proprietary new form of aprepitant) for oncology indications. Oxilio obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments, and a royalty on net sales capped at £2 million per annum.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage biotech that develops and de-risks therapeutic candidates before partnering or spinning out — comparable platform-company model to Nuformix's licensing approach.

TypeDirect peer
Description

UK-listed small-cap pharma using computational and network biology approaches to discover and repurpose existing drugs — directly comparable to Nuformix's repurposing and licensing strategy.

TypeDirect peer
Description

UK-listed respiratory-focused biotech developing novel inhaled therapies — directly comparable inhaled-delivery approach in respiratory disease.

TypeBroad incumbent
Description

Develops pamrevlumab for IPF and other fibrosis indications — incumbent competitor shaping the IPF market dynamics that NXP002 would enter.

TypeEmerging player
Description

UK-based clinical-stage biotech with a focused pipeline and partnering-led commercial strategy — similar small-cap UK public-company profile and asset-partnering trajectory.

TypeBroad incumbent
Description

Operates a 'Vant' structure of focused subsidiaries developing and licensing differentiated drug candidates — the gold-standard virtual pharma licensing model that Nuformix aspires to emulate.

TypeDirect peer
Description

Early-stage oncology-focused small-cap biotech with multiple clinical assets — comparable as a small publicly-listed pharma developer reliant on licensing/out-licensing outcomes.

TypeDirect peer
Description

Specialty pharma focused on late-stage clinical assets and out-licensing/partnering of differentiated formulations — closely aligned with Nuformix's licensing-driven model.

TypeDirect peer
Description

UK-listed small-cap biotech with a lean virtual operating model and licensing focus — directly comparable structure and scale to Nuformix.

TypeEmerging player
Description

Clinical-stage biotech focused on fibrosis therapeutics, including IPF — directly relevant as a competitor and comparable developer in Nuformix's lead indication.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuformix

Pharmaceutical Developmentnuformix.com

Nuformix is a UK-listed virtual pharmaceutical development company using solid-form science and drug repurposing to advance three preclinical/late-discovery assets — NXP001, NXP002, and NXP004 — for fibrosis and oncology, monetising them through out-licensing to pharmaceutical partners.

What Nuformix does

Nuformix plc is a UK-domiciled, London Stock Exchange-listed (ticker NFX) pharmaceutical development company that applies solid-form science and drug-repurposing expertise to create differentiated formulations of marketed compounds for fibrosis and oncology indications. Founded in 2008 (rebranded from Levrett PLC in September 2017), the company operates a virtual R&D model: three Directors plus a scientific consultant oversee development outsourced to a contracted network, with no in-house laboratory infrastructure.

Its pipeline comprises three assets. NXP002 is an inhaled formulation of tranilast for idiopathic pulmonary fibrosis (IPF), which reported positive preclinical results in March 2023 and received FDA Orphan Drug Status in March 2026, conferring US tax credits, fee waivers, and seven years of market exclusivity. NXP001 is a proprietary new form of aprepitant for oncology supportive care, exclusively licensed to Oxilio Ltd in September 2021 in a deal yielding upfront, development milestones, and royalties on net sales capped at £2 million per annum. NXP004 consists of novel co-crystal forms of olaparib (an oncology drug with annual sales exceeding £1 billion); two patent applications filed in September 2020 and November 2021 could extend exclusivity to 2040/2041 if granted.

The business model is asset-centric licensing rather than product sales. Nuformix takes each asset to a value inflection point — typically preclinical proof-of-concept or regulatory designation — before seeking global out-licensing deals with pharmaceutical partners. Capital comes from periodic equity placings (March 2021, October 2024, May 2025, October 2025) supplemented by non-dilutive grant funding. No commercial product revenue is generated; near-term cash inflows depend on licensing milestones and royalties under the Oxilio agreement.

Nuformix firmographics

Firmographics
Name
Nuformix
Legal name
Nuformix plc
Website
https://nuformix.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Nuformix is a UK-listed virtual pharmaceutical development company using solid-form science and drug repurposing to advance three preclinical/late-discovery assets — NXP001, NXP002, and NXP004 — for fibrosis and oncology, monetising them through out-licensing to pharmaceutical partners.
Ownership category
akta.pro rank

Where Nuformix is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Nuformix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: The company generates revenue through licensing its proprietary drug candidates to pharmaceutical partners. This includes upfront payments, development milestone payments, and royalties on net sales. For NXP001 licensing with Oxilio, Nuformix receives an undisclosed upfront payment, development milestone payments, and a royalty on net sales capped at £2 million per annum.
  2. Non-dilutive Grant Funding: The company seeks ongoing non-dilutive grant funding for early-stage assets that, if successful, will enable further investment in the pipeline to accelerate development and potential licensing opportunities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Nuformix product offering

Product offering

Core offering

Nuformix is a pharmaceutical development company that uses proprietary solid form science and cocrystal technology to discover, develop and patent novel drug forms of marketed compounds, repurposing them into differentiated therapeutic candidates for fibrosis and oncology. The company operates a virtual development model, advancing assets to key value inflection points before licensing them to pharmaceutical partners for upfront fees, development milestones, and royalties.

Product overview

Nuformix is a pharmaceutical development company with an early-stage pipeline of three preclinical and Phase 1-ready assets targeting fibrosis and oncology through drug repurposing. The company's core products include NXP002 (inhaled tranilast for idiopathic pulmonary fibrosis), NXP001 (novel form of aprepitant for oncology, licensed to Oxilio), and NXP004 (novel form of olaparib for oncology). Nuformix uses expertise in solid form science to discover, develop, and patent novel drug forms with improved physical properties to create differentiated products in new indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • NXP002 (inhaled tranilast) Lead asset and potential novel inhaled treatment for idiopathic pulmonary fibrosis (IPF). An inhaled formulation of tranilast delivered directly to the lungs by inhalation, targeting TGFβ/SMAD2-mediated extra-cellular matrix protein production. Preclinical data demonstrated efficient lung delivery with significant drug levels and limited systemic exposure compared to oral dosing, and dose-dependent regulation of fibrosis-relevant mediators.
  • NXP001 (proprietary new form of aprepitant) Proprietary new form of aprepitant for oncology supportive care and oncology indications, demonstrating bioavailability similar to the marketed product without requiring complex formulation. Out-licensed exclusively to Oxilio Ltd on 10 September 2021 for global research, development and commercialisation in oncology indications in exchange for undisclosed upfront, development milestones, and royalties on net sales capped at £2 million per annum.
  • NXP004 (novel co-crystal forms of olaparib)

Quantifiable outcome

  • Shares increased 12.5% following FDA Orphan Drug Status grant for NXP002
  • +2 more outcomes

Companies that use Nuformix

Customer profile

Segments2 records

Ideal customer profiles1 record

Nuformix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Nuformix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Oxilio LtdcoreOEM/ Whitelabel/ Licensing Partner · 10 September 2021Exclusive global licensing agreement signed on September 10, 2021 with Oxilio Ltd, a privately held pharmaceutical development company, for NXP001 (proprietary new form of aprepitant) for oncology indications. Oxilio obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments, and a royalty on net sales capped at £2 million per annum.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Nuformix competitors and assessment

Company assessment

Broad incumbents

  • PureTech Health: Clinical-stage biotech that develops and de-risks therapeutic candidates before partnering or spinning out — comparable platform-company model to Nuformix's licensing approach.
  • FibroGen: Develops pamrevlumab for IPF and other fibrosis indications — incumbent competitor shaping the IPF market dynamics that NXP002 would enter.
  • Roivant Sciences: Operates a 'Vant' structure of focused subsidiaries developing and licensing differentiated drug candidates — the gold-standard virtual pharma licensing model that Nuformix aspires to emulate.

Direct peers

  • e-Therapeutics: UK-listed small-cap pharma using computational and network biology approaches to discover and repurpose existing drugs — directly comparable to Nuformix's repurposing and licensing strategy.
  • Verona Pharma: UK-listed respiratory-focused biotech developing novel inhaled therapies — directly comparable inhaled-delivery approach in respiratory disease.
  • Cyclacel Pharmaceuticals: Early-stage oncology-focused small-cap biotech with multiple clinical assets — comparable as a small publicly-listed pharma developer reliant on licensing/out-licensing outcomes.
  • Redhill Biopharma: Specialty pharma focused on late-stage clinical assets and out-licensing/partnering of differentiated formulations — closely aligned with Nuformix's licensing-driven model.
  • Tiziana Life Sciences: UK-listed small-cap biotech with a lean virtual operating model and licensing focus — directly comparable structure and scale to Nuformix.

Emerging players

  • Silence Therapeutics: UK-based clinical-stage biotech with a focused pipeline and partnering-led commercial strategy — similar small-cap UK public-company profile and asset-partnering trajectory.
  • Pliant Therapeutics: Clinical-stage biotech focused on fibrosis therapeutics, including IPF — directly relevant as a competitor and comparable developer in Nuformix's lead indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nuformix social profiles

Digital presence

Nuformix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuformix leadership team

Management profile

Number of profiles

Profiles4 records

Nuformix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuformix M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuformix

What does Nuformix do?

Nuformix is a pharmaceutical development company that uses proprietary solid form science and cocrystal technology to discover, develop and patent novel drug forms of marketed compounds, repurposing them into differentiated therapeutic candidates for fibrosis and oncology. The company operates a virtual development model, advancing assets to key value inflection points before licensing them to pharmaceutical partners for upfront fees, development milestones, and royalties.

Is Nuformix a public or private company?

Nuformix is a public company. It is classified as public and is currently operating.

When was Nuformix founded?

Nuformix was founded in 2017. It employs 1 to 10 people.

Where is Nuformix based?

Nuformix is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Nuformix make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are non-dilutive Grant Funding.

Who are Nuformix's main competitors?

Broad incumbents on record are PureTech Health, FibroGen and Roivant Sciences. Direct peers are e-Therapeutics, Verona Pharma, Cyclacel Pharmaceuticals, Redhill Biopharma and Tiziana Life Sciences. Emerging players are Silence Therapeutics and Pliant Therapeutics.

Does Nuformix have an API?

No public API is recorded for Nuformix.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PMLiVENuformix proposes acquisition of BiovaraNuformix proposed acquiring Biovara, a UK respiratory drug developer, in a share-for-share merger of equals. Biovara's LipAprep, for lung cancer-related cough, completed phase 1 and is advancing to phase 2, while Nuformix's NXP002 targets fibrosis. The deal would combine two proprietary respiratory assets.The Pharma LetterNuformix proposes acquisition of BiovaraNuformix signed heads of terms for a share-for-share acquisition of UK firm Biovara, which develops LipAprep, a formulation of aprepitant for lung cancer-related cough. Nuformix shares fell 12.9% to £0.092 on the announcement. LipAprep has completed Phase I single-dose clinical development.Markets DailyNuformix (LON:NFX) Stock Falls 12% – Should You Sell?Nuformix plc's shares fell 12% during mid-day trading on Wednesday, trading as low as GBX 0.11. About 24 million shares changed hands, a 17% drop from average session volume. The company, which develops fibrosis and oncology drugs, has a market cap of £2.87 million.ProactiveinvestorsNuformix gains 19% in London trade on positive NXP002 study ahead of ERS CongressNuformix PLC reported a 19.16% increase in its share price following positive results from a pharmacokinetic study of NXP002, an inhaled therapy for idiopathic pulmonary fibrosis. The study confirmed effective drug formulation and significant pulmonary exposure levels, indicating potential for future investigational studies. Nuformix plans to present these findings at the European Respiratory Society Congress in September 2026.AdvfnNuformix PLC NXP002 Development UpdateNuformix plc reported positive preclinical results for NXP002, an inhaled treatment candidate for progressive fibrosing interstitial lung diseases, demonstrating effective pulmonary exposure and target engagement. The study confirmed the drug's ability to achieve therapeutic concentrations in the lung while limiting systemic exposure, supporting progression toward IND-enabling studies. Nuformix plans to share these findings at the European Respiratory Society Congress in Barcelona to advance discussions with prospective licensing partners.MarketScreenerNuformix interim loss narrows; aims to raise value of assetsNuformix's pretax loss narrowed to GBP346,577 in the six months to March 31, down from GBP376,668 a year earlier. The company also noted the FDA granted orphan drug designation for its lead programme tranilast lystate in idiopathic pulmonary fibrosis.YahooNuformix shares jump 12.5% as FDA grants orphan drug status for rare lung disease programmeNuformix PLC received orphan drug designation from the FDA for its NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease, causing shares to jump 12.5% to 0.29p. The designation unlocks tax credits on clinical trial costs, fee waivers, and potential seven-year marketing exclusivity if the product reaches approval. The US designation follows EMA orphan drug status granted in April 2025, with the company stating the dual designations strengthen ongoing licensing discussions with potential partners.MarketScreenerNuformix to receive milestone payments from Oxilio pactNuformix will receive immediate and near-term milestone payments from Oxilio under a revised exclusive licensing agreement for NXP001. Oxilio acquires the patent estate, while Nuformix retains further development milestones and royalties capped at GBP2 million per year. The company says the cash impact will support its NXP002 and NXP004 programmes.PR NewswireVistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS ConditionsVistaGen Therapeutics and Nuformix plc announced an agreement to develop novel cocrystalline forms of AV-101, VistaGen's CNS drug candidate, using Nuformix's proprietary cocrystal technology platform. The collaboration aims to create patentable new crystalline forms with potentially improved delivery, enhanced therapeutic profiles, and additional intellectual property protection. If successful, the companies may extend the partnership to other CNS therapeutic candidates in VistaGen's pipeline.